RxDoctor Payments Data

Kirti Solanki, MD

Family Medicine · Stockton, CANPI 1528073400

Payments from drug & device makers

$7,095in general payments, 2019–2025

Across 402 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$880
  • Johnson & Johnson$686
  • AstraZeneca$545
  • Lilly USA, LLC$529
  • Boehringer Ingelheim$498
  • Pfizer$347
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$7,078100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,095 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$266,426
Medicare patients
836
Services billed
2,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban338$131,410
XareltoRivaroxaban144$52,068
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$43,560
JardianceEmpagliflozin94$42,687
GemtesaVibegron85$35,524
JanuviaSitagliptin Phosphate53$33,513
Breo ElliptaFluticasone/Vilanterol72$31,936
OzempicSemaglutide32$29,810
TrulicityDulaglutide25$24,925
NuedextaDextromethorphan Hbr/Quinidine28$21,331
TradjentaLinagliptin54$20,759
Teriflunomide15$17,644
RybelsusSemaglutide18$16,960
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen638$12,922
Gabapentin598$11,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$347$137,127368 claims
GSKTrelegy Ellipta, Breo Ellipta$173$75,496130 claims
Boehringer IngelheimJardiance, Tradjenta$498$63,446148 claims
Johnson & JohnsonXarelto$686$52,068144 claims
Novo NordiskOzempic, Rybelsus$91$46,77050 claims
MerckJanuvia, Janumet$104$43,71292 claims
Lilly USA, LLCTrulicity, Mounjaro$529$36,07136 claims
Sumitomo Pharma America, Inc.Gemtesa$129$35,52485 claims
Avanir Pharmaceuticals, Inc.Nuedexta$146$21,33128 claims
AstraZenecaSymbicort$545$11,04041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →